Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
about
Phloroglucinol inhibits the bioactivities of endothelial progenitor cells and suppresses tumor angiogenesis in LLC-tumor-bearing miceEarly sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibCollateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.Effectiveness of medical supportive team for outpatients treated with sorafenib: a retrospective studyVEGF inhibition, hypertension, and renal toxicityHand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.Reversibility of regorafenib effects in hepatocellular carcinoma cells.Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.Management of hypertension in angiogenesis inhibitor-treated patients.Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case reportToxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management.Toxicity of sorafenib: clinical and molecular aspects.The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.Meta-analysis of dermatological toxicities associated with sorafenib.Bevacizumab-induced hypertension: pathogenesis and management.Drug-induced acneiform eruption.Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.Targeted therapies for renal cell carcinoma: review of adverse event management strategies.Sorafenib in melanoma.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.Endoplasmic reticulum stress and angiogenesis: is there an interaction between them?Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.Renal effects of targeted anticancer therapies.Onco-nephrology: a decalogue.Safety of available treatment options for renal cell carcinoma.Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
P2860
Q28482182-3DF8F6A8-A81B-4B81-90A3-294A23A2E174Q28482219-1BC3D632-657B-468C-AAEC-9DB05D6AF85DQ28550300-38082B70-E889-4BD5-AAB9-72A71A59A5CAQ30486078-9D8767E3-E923-4205-93D0-90AF8446F107Q33442681-75C776D2-B4C0-4EAF-97D9-77E05453A625Q33885559-4C3D8196-5952-4FC5-AED5-8F76A4196CE6Q33916002-DF374E1E-E9D2-41BC-AB2B-EF9F5F6363D5Q34005875-1FBF609D-E8F8-493E-A815-B46DC848CF03Q34036032-4BBB56D4-FD53-4D37-A571-5591CF5431A5Q35419004-D574BAC6-7E97-4481-BCA7-5326B860DE5CQ35553882-57272D76-396A-43D7-8CA5-88C91AF4FF4EQ35584920-47A4FEBA-F2F4-4F56-B3ED-2A040D982940Q35705188-ED555A29-3769-4D5B-8A77-446B374B808AQ36368199-23BA82E3-32C1-4D5E-8764-29104BD5D58AQ37103555-7BD9BB5F-F8AC-4FED-9633-B0B1E8929EDBQ37283073-24F40F84-7EBA-4DD9-96AB-1B95CD76C5D9Q37332505-CA3875CA-8B75-40C4-8984-6797E15F5E51Q37346912-28EAE297-E820-4261-BE49-E227A6CB1542Q37371312-8B2C97EB-D680-4C8F-84BF-217BE3937590Q37403333-F8B4DF4C-4139-49E8-A99F-4ABA93850C17Q37508022-0E768DF0-DFB4-40FC-811B-155D46843691Q37630186-44D880DA-8B99-4EA2-BF8C-E72996124C25Q37676226-4D1F52A7-1D5F-4C4A-AECF-A9FEADB2CD2AQ37729290-03DA4826-B62A-40F9-8B62-39A34D681CFFQ37830778-0F21B2F0-7F1C-4455-8EC1-A1CE14DD3D5AQ37851857-0A1F58D7-F258-423F-988D-E7BAFC7565FBQ37867169-E3AD062F-7079-45BB-AFF2-E2F524AB1FD6Q37882684-AD8F98E1-344D-4F4B-A61A-AEA54264AF1FQ37888655-85E80A55-2D7A-42F7-89D9-E3EA6A77A134Q37930711-A5E08091-D8D6-41A2-9C9A-D382032719A5Q37974894-BCDBF3F4-7B09-4887-BCDB-7BEC360DB0BAQ37990977-CA587D8D-4A66-40D3-9157-B9AA58C57D4AQ38076349-0BB7EA57-EA0D-410B-9000-A002FED4716BQ38110320-0E32D5BA-C3B8-41CA-90FA-32C977B63235Q38176096-800BD640-DD45-4B90-86EF-D7235C159A36Q38237495-0E3E5ABC-04CD-4652-84EA-75FD5016F59BQ38367168-0C2BE384-D320-4B16-A12A-EF7E373A9072Q38581085-37761E4C-E016-4BA9-B506-C58E8487852CQ38824719-B9838476-52C2-4101-80CB-6BC6C6C9C6E6Q38827793-952BB4F0-13FB-44C7-85BC-0EB66E32FAE6
P2860
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Uncovering Pandora's vase: the ...... se of sorafenib and sunitinib.
@en
Uncovering Pandora's vase: the ...... se of sorafenib and sunitinib.
@nl
type
label
Uncovering Pandora's vase: the ...... se of sorafenib and sunitinib.
@en
Uncovering Pandora's vase: the ...... se of sorafenib and sunitinib.
@nl
prefLabel
Uncovering Pandora's vase: the ...... se of sorafenib and sunitinib.
@en
Uncovering Pandora's vase: the ...... se of sorafenib and sunitinib.
@nl
P2093
P1476
Uncovering Pandora's vase: the ...... ase of sorafenib and sunitinib
@en
P2093
P2860
P2888
P304
P356
10.1007/S10238-007-0145-8
P577
2007-12-01T00:00:00Z